Genprex Inc.

3.40-0.4200-10.99%Vol 1.94M1Y Perf 64.71%
Apr 20th, 2021 16:00 DELAYED
BID3.32 ASK3.63
Open3.86 Previous Close3.82
Pre-Market- After-Market-
 - -  - -%
Target Price
7.00 
Analyst Rating
Strong Buy 1.00
Potential %
105.88 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap147.14M 
Earnings Rating
Neutral
Price Range Ratio 52W %
25.13 
Earnings Date
13th May 2021

Today's Price Range

3.223.88

52W Range

1.957.72

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-16.46%
1 Month
-33.07%
3 Months
-9.33%
6 Months
4.62%
1 Year
64.71%
3 Years
-20.56%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
GNPX3.40-0.4200-10.99
AAPL133.11-1.7300-1.28
GOOG2 293.63-8.7700-0.38
MSFT258.26-0.4800-0.19
XOM55.29-1.1900-2.11
WFC42.54-1.3400-3.05
JNJ166.483.79002.33
FB302.650.41000.14
GE13.06-0.4000-2.97
JPM149.27-3.3800-2.21
Earnings HistoryEstimateReportedSurprise %
Q02 2020-0.19-0.1236.84
Q01 2020--0.20-
Q03 2019-0.22-0.1531.82
Q02 2019-0.21-0.24-14.29
Q01 2019-0.23-0.1439.13
Q04 2018-0.18-0.23-27.78
Q03 2018-0.18-0.1516.67
----
Earnings Per EndEstimateRevision %Trend
12/2020 QR-0.280.00-
12/2020 QR-0.280.00-
12/2020 FY-0.890.00-
12/2021 FY0.90--
Next Report Date13th May 2021
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume1.94M
Shares Outstanding43.28M
Trades Count6.32K
Dollar Volume5.48M
Avg. Volume1.45M
Avg. Weekly Volume842.87K
Avg. Monthly Volume1.01M
Avg. Quarterly Volume1.47M

Genprex Inc. (NASDAQ: GNPX) stock closed at 3.4 per share at the end of the most recent trading day (a -10.99% change compared to the prior day closing price) with a volume of 1.98M shares and market capitalization of 147.14M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 8 people. Genprex Inc. CEO is J. Rodney Varner.

The one-year performance of Genprex Inc. stock is 64.71%, while year-to-date (YTD) performance is -18.07%. GNPX stock has a five-year performance of %. Its 52-week range is between 1.95 and 7.72, which gives GNPX stock a 52-week price range ratio of 25.13%

Genprex Inc. currently has a PE ratio of -7.50, a price-to-book (PB) ratio of 5.54, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -110.43%, a ROC of -114.38% and a ROE of -114.23%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Genprex Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Genprex Inc.’s next earnings report date is 13th May 2021.

The consensus rating of Wall Street analysts for Genprex Inc. is Strong Buy (1), with a target price of $7, which is +105.88% compared to the current price. The earnings rating for Genprex Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Genprex Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Genprex Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 20.36, ATR14 : 0.51, CCI20 : -143.30, Chaikin Money Flow : -0.09, MACD : -0.41, Money Flow Index : 42.96, ROC : -11.37, RSI : 36.83, STOCH (14,3) : 6.61, STOCH RSI : 0.00, UO : 29.45, Williams %R : -93.39), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Genprex Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (100.00 %)
0
0 (0.00 %)
Moderate Buy
0 (0.00 %)
0
0 (0.00 %)
Hold
0 (0.00 %)
0
1 (100.00 %)
Moderate Sell
0 (0.00 %)
0
0 (0.00 %)
Strong Sell
0 (0.00 %)
0
0 (0.00 %)
Summary RatingStrong Buy
1.00
-Hold
3.00

Genprex Inc.

Genprex Inc is a clinical stage gene therapy company. It is engaged in developing a new approach to treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells and modulates the immune response against cancer cells.

CEO: J. Rodney Varner

Telephone: (877) 774-4679

Address: 1601 Trinity Street, Building B, Austin 78712-1885, TX, US

Number of employees: 8

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

0%100%

Bearish Bullish

53%47%

Bearish Bullish

52%48%

Bearish Bullish

57%43%

News

Stocktwits